Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-7.31% $3.17
America/New_York / 1 sep 2021 @ 00:00
FUNDAMENTALS | |
---|---|
MarketCap: | 226.39 mill |
EPS: | 0 |
P/E: | 0 |
Earnings Date: | Aug 16, 2021 |
SharesOutstanding: | 71.42 mill |
Avg Daily Volume: | 0.157 mill |
RATING 2022-02-09 |
---|
B+ |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Neutral | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/20 | 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | |
Revenue | n/a | |||||
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 0 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
N/A |
Company: PE 0 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 2.73 - 3.61 ( +/- 13.75%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-07-27 | Selsky Clifford | Buy | 101 579 | Common Stock, par value $0.005 per share |
2021-07-27 | Aronstam Peter | Buy | 141 370 | Common Stock, par value $0.005 per share |
2021-07-27 | Selsky Clifford | Buy | 0 | |
2021-07-27 | Aronstam Peter | Buy | 0 | |
2021-07-27 | Barbarick Steve K | Buy | 0 |
INSIDER POWER |
---|
0.00 |
Last 91 transactions |
Buy: 2 702 906 | Sell: 404 086 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.17 (-7.31% ) |
Volume | 0.116 mill |
Avg. Vol. | 0.157 mill |
% of Avg. Vol | 74.07 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.